CSPC Innovation's (300765.SZ) subsidiary initiates Phase I/II clinical trial of SYS6088

Zhitong Finance APP news, CSPC Innovation (300765.SZ) announced that its controlling subsidiary, CSPC Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Biopharmaceutical"), has recently initiated a Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic (PK) characteristics, and efficacy of SYS6088 in patients with advanced/metastatic solid tumors, consisting of dose escalation, PK expansion, and cohort expansion.